TraceLink Due Diligence
Run due diligence on TraceLink: check compliance and get alerts when suppliers change.
United States · www.tracelink.com · 16 vendors
TraceLink operates the world's largest end-to-end digital network platform for intelligent orchestration of the supply chain, primarily serving the life sciences and healthcare industries. It provides solutions for global connectivity, visibility, and traceability of healthcare products. The company aims to ensure that patients receive the medicines they need safely and securely, while also helping businesses comply with regulatory mandates.
Resilience scores
- Digital Sovereignty: 75
- Digital Resilience: 8
- Financial Resilience: 7
Technology vendors
- Anysphere, Inc. — Technology — United States
- Apple Inc. — Technology — United States
- Jamf — Technology — United States
- and 13 more
Services catalogue
2 services in catalogue across 1 category; runs on 16 sub-vendors.
- Serial Number Repository Manager
- Serialization
Insights
Last updated 2026-07-30 · revision 2
16 direct vendors, 190 subvendors
Direct vendors by controlling owner country (sample)
- Australia: 1
- United States: 12
- Czech Republic: 1
Subvendors by controlling owner country (sample)
- Brazil: 1
- Romania: 1
- Japan: 2
Compliance
13 in-scope frameworks identified; showing 3.
ISAE 3000 (source) — Evidence found
Evidence: https://www.tracelink.com/legal-and-trust/certifications-and-attestations, https://www.tracelink.com/sites/default/files/2025-12/TraceLink-2025-Type-2-SOC-2-ISAE-3000-Confirmation-of-Audit-Opinion-TraceLink-SaaS-Solutions-and-Opus-Platform.pdf, https://www.iaasb.org/publications/international-standard-assurance-engagements-isae-3000-revised-assurance-engagements-other-audits-or
SOC 2 (source) — Evidence found
Evidence: https://www.tracelink.com/legal-and-trust/certifications-and-attestations, https://www.tracelink.com/sites/default/files/2025-12/TraceLink-2025-Type-2-SOC-2-ISAE-3000-Confirmation-of-Audit-Opinion-TraceLink-SaaS-Solutions-and-Opus-Platform.pdf, https://us.aicpa.org/interestareas/frc/assuranceadvisoryservices/aicpasoc2report
HIPAA (source) — No public evidence
Evidence: https://www.tracelink.com/legal-and-trust-center, https://www.tracelink.com/legal-and-trust/certifications-and-attestations, https://www.tracelink.com/supply-chain-orchestration/healthcare-provider, https://www.tracelink.com/supply-chain-orchestration/retail-pharmacy, https://www.hhs.gov/hipaa/for-professionals/index.html
Financials
Three-year financials
- 2025:
- 2024:
- 2023:
Financial Resilience Score: 7/10
TraceLink demonstrates solid financial resilience underpinned by a defensible business model, though public financial opacity limits precise assessment. As a privately held Delaware C-corp, TraceLink has no obligation to publish audited financials, but qualitative indicators point to a resilient franchise: a recurring SaaS revenue model with multi-year subscriptions to blue-chip pharma customers, strong regulatory tailwinds from DSCSA/FMD and equivalent global serialization mandates, and powerful network effects across 291,000+ authenticated members and 1,600+ direct customers. The company achieved unicorn status with a $200M Series F in June 2021 led by Goldman Sachs and Georgian, providing meaningful capital runway. Third-party estimates place annual revenue in the $100–200M range, though these are unverified. Key risks include concentration in the life sciences vertical, dependence on regulatory cycles (post-DSCSA deadline renewal/pricing pressure), and the need to eventually refinance or IPO in a more disciplined valuation environment than 2021. Aggressive investment in agentic AI (OPUS Agents) likely pressures near-term operating profitability. Overall, TraceLink appears financially resilient with strong customer stickiness and network moats, but private-company opacity and reliance on a 2021-vintage funding round warrant a moderate-to-strong rather than top-tier score.
Key strengths: Recurring SaaS subscription revenue model with high visibility and gross retention, Deep regulatory moat via DSCSA, FMD, and global serialization compliance, Two-sided network effects across 291,000+ members and 1,600+ direct customers, Blue-chip customer base including Merck, Alexion, Merz Therapeutics, Boston Medical Center, $200M Series F (2021) at >$1B valuation led by Goldman Sachs and Georgian, Product expansion beyond track-and-trace into MINT, POET, and OPUS Agents, Strong industry recognition (IDC MarketScape leader, Fast Company Most Innovative)
Risk factors: Post-DSCSA deadline renewal pressure and potential price compression, No public financials, credit ratings, or audited disclosures, Last major funding round in 2021 at peak SaaS valuations; refinancing risk, Concentration in life sciences vertical exposes to pharma IT budget cycles, Competition from SAP, Oracle, Systech, rfxcel, Movilitas, and cloud EDI platforms, Elevated R&D and go-to-market spend on agentic AI pressuring near-term profitability
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.